Usefulness of DORNASE in COVID-19 on HFNO
- Registration Number
- NCT05139901
- Lead Sponsor
- University Medical Centre Ljubljana
- Brief Summary
COVID-19 pneumonia manifests among others with a thick bronhial secretion. It contains an increased number of neutrophil extracellular traps (NETs), formed during netosis. DNA is a major component in NETs. DNAse alfa (Pulmozyme®, Roche) is a recombinant human enzyme, registered for inhalations in patients with Cystic fibrosis, in which NETs are also a typical characteristic. DNAse alfa inhalations are typically well tolerated and with no major side effects. Some initial reports exist of using DNAse alfa inhalations in COVID-19 patients, that had benefitial effects. There are some trials registered with ClinicalTrials, investigating the usufulness of DNAse alfa in intubated patients, but the investigators have no knowledge of a trial, investigating the usufulness of this drug in patients receiving High Flow Nasal Oxygen therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 10
- Positive SARS-CoV-2 RNA PCR swab
- inflamatory phase of infection
- HFNO
- pregnancy
- previous treatment with DNAse alfa
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 4% saline Saline 4% Saline inhalations twice daily Pulmosyme Dornase Alfa DNAse alpha inhalations twice daily
- Primary Outcome Measures
Name Time Method Intubations 7 days Number of intubations necessary
- Secondary Outcome Measures
Name Time Method PaO2/FiO2 7 days Increase in PaO2/FiO2 ratio
inflamation 7 days Reduction of inflamation
Trial Locations
- Locations (1)
University Medical Centre Ljubljana
🇸🇮Ljubljana, Slovenia